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Abstract: 5-ﬂ  uorouracil/leucovorin, with or without oxaliplatin or irinotecan, is the most 
widely used treatment for the metastatic as well for the adjuvant setting of colorectal cancer. 
These agents are administered intravenously (by bolus or infusion), thereby causing signiﬁ  cant 
inconvenience to patients. Capecitabine, an oral ﬂ  uoropyrimidine, has been demonstrated to be at 
least as effective as bolus 5-ﬂ  uorouracil/leucovorin in terms of time to disease progression, time 
to treatment failure, and overall survival, but achieves signiﬁ  cantly higher response rates and has 
the advantage of oral administration. In addition, capecitabine has improved tolerability with a 
signiﬁ  cantly lower incidence of stomatitis, nausea, and alopecia than 5-ﬂ  uorouracil/leucovorin. 
Clinical trials have shown that combination therapy with capecitabine and either irinotecan or 
oxaliplatin is effective and well tolerated. The combination of capecitabine plus oxaliplatin, 
with or without bevacizumab, could represent the new standard of care for metastatic as well 
as surgically resected high-risk stage II and III colon cancer patients. Some pharmacoeconomic 
analyses have highlighted that capecitabine plus oxaliplatin results in cost savings compared 
with 5-ﬂ  uorouracil/leucovorin plus oxaliplatin. 
Keywords: capecitabine, colon cancer, rectal cancer, adjuvant treatment, combination 
chemotherapy
Introduction 
Colorectal cancer (CRC) is one of the most common malignancies occurring in men 
and women in the Western world, and is associated with a high rate of mortality (Jemal 
et al 2005). Approximately 55% of patients present with advanced disease (ie, cancer 
that is metastatic or so locally invasive that surgical resection is insufﬁ  cient for cure). 
Diagnosis of CRC at a later stage results in 5-year survival rates of 67% in patients 
whose cancer has spread to regional lymph nodes, and 10%–30% for those in whom 
CRC has spread to distant organs such as the liver.
For patients with metastatic disease, surgery has a limited role, because only when 
it allows a complete resection of organ metastases does it have a relevant impact on 
survival of patients. In the remaining cases, chemotherapy, although not curative, may 
increase the time to disease progression and the overall survival. 
5-ﬂ  uorouracil (5FU), the ﬂ  uorinated analogue of uracil originally synthesized 
in 1957 as an anticancer drug, has shown activity in a variety of solid tumours. 
Cytotoxicity of 5FU resulted from both the incorporation of 5FU into RNA, and the 
depletion of thymidine following the binding of 5FU with the enzyme thymidilate 
synthase (TS). The binding of 5FU to TS has been demonstrated to increase and sta-
bilize in the presence of leucovorin (LV).
The combination of 5FU plus LV has represented the mainstay for the treatment 
of metastatic colorectal cancer for some decades. Indeed, several trials have investi-
gated different doses and schedules of delivery of such combination in comparison Therapeutics and Clinical Risk Management 2007:3(3) 422
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with single agent 5FU. A recent meta-analysis of such trials 
revealed that the addition of LV to 5FU was able to signiﬁ  -
cantly increase not only the response rate (RR), but also the 
overall survival (OS) of patients treated with the combination 
(The Meta-Analysis Group in Cancer 2004). 
As for the adjuvant setting, up to few years ago a treat-
ment including 5FU 450 mg/m2 plus LV 20 mg/m2, both 
given i.v. for 5 days monthly for 6 cycles (Mayo Clinic 
regimen), represented the standard adjuvant treatment for 
surgically resected stage III and high-risk stage II colon 
cancer (Gill et al 2004). More recently, a biweekly regimen 
with LV 200 mg/m2 infused over 2 hours plus mixed bolus 
(400 mg/m2) and infusional (600 mg/m2 in 22 hours) 5FU for 
2 days (LV5FU2 regimen) has replaced in clinical practice 
(at least in Europe) the bolus regimen, because of its better 
tolerability (André et al 2003).
Capecitabine as single-agent in the 
management of metastatic CRC
Capecitabine is a pro-drug of 5FU. Assumed orally, its bio-
availability is almost 100%, and it exhibits a linear increase 
of its Cmax and AUC with dosage increases. After a standard 
dosage of 1250 mg/m2, the peak plasma concentration is 
achieved in 1.5–2 hours. Capecitabine is metabolized to 5FU 
through 3 metabolic steps. Once the drug is absorbed through 
the intestine, the carboxylesterase of the liver cells con-
verts capecitabine to 5′-deoxy-5-ﬂ  uorocytidine (5′-DFCR). 
5′-DFCR is then metabolized to 5′-deoxy-5-ﬂ  uorouridine 
(5′-DFUR) by cytidine deaminase, an ubiquitous enzyme 
with high concentration in the liver, plasma, and tumour tis-
sue. Finally, 5′-DFUR is converted to the active drug 5FU by 
thymidine phosphorylase, which is present in amounts 3–10 
times higher in various solid tumours compared with the 
normal adjacent tissue (Figure 1). The higher concentration 
of thymidine phosphorylase in tumour tissues leads to a ﬁ  nal 
concentration of 5FU that is 3 times higher than in normal 
tissues (Ishikawa et al 1998; Miwa et al 1998). 
Based on these assumptions, capecitabine has been 
assessed in patients affected by metastatic CRC. After a phase 
II randomized trial, deﬁ  ning the recommended dosage and 
schedule for capecitabine as 1250 mg/m2 twice daily for 2 
consecutive weeks and 1 week of rest every 3 weeks (Van 
Cutsem et al 2000), 2 phase III randomized trials compared 
capecitabine as a single agent with the standard 5FU/LV 
treatment (Mayo Clinic) regimen in patients with metastatic 
CRC. Both trials had the same primary end-point, ie, to 
demonstrate that capecitabine was at least as effective as 
5FU/LV in terms of RR. Capecitabine was assumed at the 
recommended total daily dose of 2500 mg/m2 for 2 weeks 
of treatment and 1 week of rest, while 5FU was given at 
425 mg/qm2 i.v. preceded by LV 20 mg/m2 i.v., for 5 days, 
recycling every 4 weeks. In one of these trials, capecitabine 
actually resulted to produce a signiﬁ  cantly greater RR than 
the Mayo Clinic regimen (25.8% vs 11.6%) (Hoff et al 2001). 
Median failure-free survival (FFS) (4.1 vs 3.1 months), 
progression-free survival (PFS) (4.3 vs 4.7 months), and 
OS (12.5 vs 13.3 months) were not statistically different, 
supporting the conclusion that capecitabine is at least as 
effective as the 5FU/LV regimen also for these outcomes. 
As for safety, patients treated with capecitabine were less 
likely to experience clinical grade 4 toxicity than those treated 
with 5FU/LV (2.7% vs 4.8%). Incidence of severe diarrhea 
was similar (14% vs 15%). Conversely, patients treated with 
5FU/LV experienced more severe stomatitis (16% vs 3%), 
while capecitabine led to a higher incidence of hand and 
foot syndrome (18% vs 1%). In the other trial (Van Cutsem 
et al 2001), RR was 18.9% for capecitabine and 15% for 
5FU/LV, proving that capecitabine was at least equivalent to 
the Mayo Clinic regimen. No difference in median FFS (4.2 
vs 4.0 months) or PFS (5.2 vs 4.7 months) were observed 
between the two groups. Survival was also equivalent, with 
a median of 13.2 months for the capecitabine group, and 12.1 
months for 5FU/LV group. Also in this trial, severe stomatitis 
occurred more frequently with 5FU/LV (13.3% vs 1.3%), 
while proportion of patients suffering from severe diarrhea 
(10.7% vs 10.4%) was similar. Grade 3 hand-foot syndrome 
was seen in 16.2% vs 0.3% of patients. A pooled analysis of 
these two studies underlined that signiﬁ  cantly fewer patients 
required hospitalization for treatment-related adverse events 
(11.6% vs 18.8%), and fewer physician visits were required 
for treatment administration with capecitabine than with 
5FU/LV (4 vs 15 in a 12-week period) (Van Cutsem et al 
2004) (Table 1). 
Furthermore, capecitabine as been speciﬁ  cally assessed 
for the treatment of elderly (aged 70 years) patients in 
a Spanish phase II trial. The dosage was the same as for 
younger patients (ie, 1250 mg/m2 twice daily orally on days 
1–14 every 3 weeks), but it was reduced to 950 mg/m2 in 
the presence of a creatinine clearance of 30–50 mL/min. The 
RR was 24% among 51 treated patients, and median times 
to disease progression and overall survival were 7 months 
and 11 months, respectively. Treatment was extremely well 
tolerated, with grade 3 and 4 adverse events (mainly, diarrhea, 
hand-foot syndrome, and thrombocytopenia) observed in Therapeutics and Clinical Risk Management 2007:3(3) 423
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only 6 patients (12%). Of note, 14 patients (40%) of 35 
assessable patients had a clinical beneﬁ  t for a median length 
of 4 months (Feliu et al 2005).
These findings, along with the good compliance of 
patients for an oral therapy, represented a strong rationale for 
combining capecitabine with either oxaliplatin or irinotecan 
in the ﬁ  rst line treatment of metastatic colorectal cancer. 
Indeed, irinotecan was the ﬁ  rst drug that, in combination 
with 5FU/LV, was demonstrated to increase the RR, and to 
improve the PFS and OS of patients, in comparison with 5FU/
LV alone. In the Saltz et al study (Saltz et al 2000), a weekly 
for 4 weeks every 6 weeks regimen of irinotecan 125 mg/m2 
plus 5FU 500 mg/m2 and LV 20 mg/m2, given on the same 
day, was compared with the standard daily for 5 consecutive 
days every 4 weeks (Mayo Clinic) regimen. In this trial, the 
combination regimen produced a signiﬁ  cantly greater RR 
(39% vs 21%), and a signiﬁ  cantly longer median PFS (7.0 
vs 4.3 months) and OS (14.8 vs 12.6) than the Mayo Clinic 
regimen. Another trial compared the addition of irinotecan 
(either 80 or 180 mg/m2) with the weekly (AIO regimen) or 
biweekly (LV5FU2) infusional regimen, respectively: most 
patients were treated with the LV5FU2 regimen, while 25% 
of them received the weekly AIO regimen (with or without 
irinotecan) (Douillard et al 2000). Addition of irinotecan 
to both regimens signiﬁ  cantly increased the proportion of 
conﬁ  rmed RR (41% vs 23%), the median PFS (6.7 vs 4.4 
months), and OS (17.4 vs 14.1 months). 
Subsequently, several randomized trials have compared 
the combination of oxaliplatin with LV5FU2. In the study of 
de Gramont et al, the FOLFOX4 (oxaliplatin 85 mg/m2 on 
day 1 added to LV5FU2 regimen) obtained a signiﬁ  cantly 
greater RR (51% vs 22%), and a longer PFS (9.0 vs 6.2 
months) than the LV5FU2 regimen (de Gramont et al 2000). 
Pluzanska et al (2005) reported at the 2005 ASCO Meeting 
Figure 1 Enzymatic conversion of capecitabine to 5FU.
Abbreviations:  CE, carboxylesterase; CyD, cytidine deaminase.
Table 1 Summary of randomized trials comparing capecitabine with 5FU/LV (Mayo Clinic) regimen in metastatic colon cancer
Authors   No. pts  Regimen  RR (95% CI)  Median PFS  Median OS
Hoff et al 2001  605  Capecitabine 1250 mg/m2   25.8  4.3 months  12.5 months
    twice daily for 2–3 weeks  (21.0%–31.2%)
    LV 20 mg/m2 5FU 425 mg/m2  11.6  4.7 months  13.3 months
    i.v. days 1–5 every 4 weeks  (8.2%–15.7%)  p = 0.72  p = 0.97
Van Cutsem et al 2001  602  Capecitabine 1250 mg/m2   18.9  5.2 months  13.2 months
    twice daily for 2 of 3 weeks  (14.7%–23.8%) 
    LV 20 mg/m2 5FU 425 mg/m2   15.0  4.7 months  12.1 months
    i.v. days 1–5 every 4 weeks  (11.1%–19.5%)  p = 0.65  p = 0.33
Abbreviations: 5FU, 5-ﬂ  uorouracil; LV, leucovorin; OS, overall survival; PFS, progression-free survival; RR, response rate.Therapeutics and Clinical Risk Management 2007:3(3) 424
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that adding oxaliplatin signiﬁ  cantly increased the RR (54% 
vs 30%) and PFS (8.0 vs 6.0 months) in comparison with 
infusional 5FU/LV regimens. However, in neither trial was 
OS signiﬁ  cantly prolonged (median, 16.2 vs 14.7 months; 
and 15.9 vs 15.2 months, respectively). Moreover, Grothey 
et al (2002) added oxaliplatin to the AIO weekly infusional 
5FU regimen, and reported a signiﬁ  cantly higher RR (48.3% 
vs 22.6%) and PFS (7.9 vs 5.3 months) in comparison with 
the Mayo Clinic regimen. Also in this case median OS was 
not signiﬁ  cantly improved, probably because of effective 
salvage therapy (19.7 vs 16.1 months).
Capecitabine in combination 
regimens for treating metastatic CRC
On the basis of such evidences, capecitabine was assessed in 
combination with oxaliplatin in a large, multicenter, interna-
tional phase II trial. In a population of 96 patients, recruited 
with no upper age-limit, the combination of oxaliplatin 130 
mg/m2 given on day 1, and capecitabine 2000 mg/m2 daily for 
2 weeks, recycling every 21 days, obtained a RR in 55% of 
patients, with a median PFS of 7.7 months, and a median OS 
of 19.5 months. This treatment was extremely well tolerated, 
causing severe hematologic toxicity in a negligible propor-
tion of patients (neutropenia, 7%; thrombocytopenia, 4%), 
while the main non-hematologic side effects were diarrhea 
(16%), vomiting 13%, and neuropathy (16%) (Cassidy et al 
2004). Interestingly, a retrospective analysis on the activity 
and toxicity of this regimen showed no difference between 
patients aged less than 65 years and elderly patients (Twelves 
et al 2005a). Furthermore, a phase II trial speciﬁ  cally ad-
dressed the tolerability and activity of the XELOX regimen 
in elderly (aged 70 years) patients. An intra-patient dose 
escalation of both drugs over the ﬁ  rst 3 cycles was planned, 
starting with absolutely safe initial dosages (oxaliplatin 85 
mg/m2, capecitabine 2000 mg/m2 for 2 weeks, recycling every 
3 weeks), in order to avoid unexpected toxicity. However, 
after an interim analysis on the ﬁ  rst 35 patients, the design 
of the study was modiﬁ  ed, and the delivery of capecitabine 
was kept unchanged (2000 mg/m2) over the whole treat-
ment, while oxaliplatin was escalated from an initial dose 
of 85 mg/ m2 to 130 mg/ m2 over the ﬁ  rst 3 cycles. Forty per 
cent of patients showed a major response, regardless of the 
schedule employed, and for the whole series of 76 patients, 
the median PFS was 8.5 months, and the median OS was 
14.4 months. The amended schedule was extremely well 
tolerated, only 7% of patients complaining of severe diarrhea 
(Comella et al 2005a). Comparable results were reported by 
other investigators with similar combinations of oxaliplatin 
and capecitabine in phase II trials, regardless of the age of 
patients (Scheithauer et al 2003; Comella et al 2005b; Feliu 
et al 2006).
These ﬁ  ndings prompted the activation of prospective, 
randomized trials to assess the substitution of 5FU with 
capecitabine in combination with oxaliplatin (Table 2). A 
German trial compared the FUFOX regimen, in which 5FU 
2000 mg/m2 (infused over 24 hours), LV 500 mg/m2, and 
oxaliplatin 50 mg/m2 were given weekly for 4 weeks and 2 
weeks of rest, with the CAPOX regimen, in which oxaliplatin 
70 mg/m2 on days 1 and 8, and capecitabine 2000 mg/m2 daily 
for 2 weeks, were recycled every 3 weeks. In this study, in 
Table 2 Summary of randomized phase III trials about the combination of capecitabine plus oxaliplatin in metastatic colon cancer
Authors   No. pts  Regimen  RR   Median PFS  Median OS
Arkenau et al 2005  476  Oxaliplatin 70 mg/m2 days 1 and 8  47%  7.8 months  16.3 months
    Capecitabine 1000 mg/ m2 twice
    daily for 2 of 3 weeks
   or
    Oxaliplatin 50 mg/m2
    LV 500 mg/m2, 5FU 2000 mg/m2  49%  8.0 months  17.2 months
    (infused over 24 hours), weekly    p = 0.11  p = 0.72
    for 4 of 6 weeks
Massuti et al 2006  342  Oxaliplatin 130 mg/m2 day 1  37%  8.9 months  18.8 months
    Capecitabine 1000 mg/m2 twice    
    daily for 2 of 3 weeks 
   or         
    Oxaliplatin 85 mg/m2 days 1 and 15  45%  9.5 months  21.2 months 
    5FU 2.25 g/ m2 48-hour i.v. infusion    p = 0.154  p = 0.105 
    weekly for 6 weeks
Abbreviations: 5FU, 5-ﬂ  uorouracil; LV, leucovorin; OS, overall survival; PFS, progression-free survival; RR, response rate.Therapeutics and Clinical Risk Management 2007:3(3) 425
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which 476 patients were enrolled, no difference in RR (47% 
vs 49%), median PFS (7.0 vs 8.0 months) or OS (16.3 vs 17.2 
months) were seen between patients treated with CAPOX 
and FUFOX (Arkenau et al 2005). 
A Spanish trial compared the standard XELOX regimen 
given every 3 weeks with a weekly 48-hour infusion of 5FU 
2250 mg/m2 plus oxaliplatin 85 mg/m2 given biweekly. RR 
(37% vs 45%) as well as was median PFS (8.9 vs 9.5 months) 
and OS (18.8 vs 21.2 months) were not signiﬁ  cantly different. 
The XELOX regimen produced a slightly lower occurrence 
of severe diarrhea (14% vs 24%) (Massuti et al 2006).
In the TREE-1 study, patients were randomly allocated 
to receive either the mFOLFOX (oxaliplatin 85 mg/m2 and 
LV 350 mg/m2 on day 1, 5FU 400 mg/m i.v. bolus and 2400 
mg/sqm2 i.v. 46-hour infusion) every 2 weeks, the bFOL 
regimen (oxaliplatin 85 mg/m2 on day 1, and 5FU 500 mg/
m2 plus LV 20 mg/m2 i.v. on days 1 and 8, every 2 weeks), 
or the XELOX regimen every 3 weeks. In this study, 147 
patients were enrolled. The RR yielded by each regimen was 
43%, 22%, and 35%. The median PFS were 8.7, 6.9, and 
5.9 months, while the corresponding median OS were 19.2, 
17.9, and 17.2 months, respectively. However, it should be 
noted that the XELOX regimen produced more frequently 
a severe dehydration (27%) as opposed to the mFOLFOX 
(8%) or bFOL regimen (12%), while severe diarrhea had a 
similar occurrence with all the regimens (31%, 33%, 26%). 
The safety advantage of the XELOX regimen was limited to 
the occurrence of neutropenia, which was much lower (15%) 
than that reported with mFOLFOX (53%) or bFOL (18%). 
Therefore, when bevacizumab was added to these treatments 
(5 mg/kg i.v biweekly with mFOLFOX and bFOL regimens, 
7.5 mg/kg i.v. triweekly with XELOX) in the second part of 
the study (TREE-2 study), the dosage of capecitabine in the 
XELOX was reduced from 2000 to 1750 mg/m2 daily for 2 
weeks. Additional 213 patients were included in the TREE-2 
study, and the addition of bevacizumab improved all the 
efﬁ  cacy parameters in comparison with the previous part of 
the study (mFOLFOX + bevacizumab: RR, 53%; PFS, 9.9 
months, OS, 26.0 months; bFOL + bevacizumab: RR, 41%; 
PFS, 8.3 months, OS, 20.7 months; XELOX + bevacizumab: 
RR, 48%; PFS, 10.3 months, OS, 27.0 months). The reduc-
tion of capecitabine signiﬁ  cantly reduced the occurrence of 
dehydration (8%) produced by XELOX+ bevacizumab in this 
cohort of patients (Hochster et al 2006) (Table 1). 
At the 2007 ASCO Gastrointestinal Cancer Symposium, 
the results of the NO16966 trial were reported. This study 
was initially aimed at demonstrating the non-inferiority of 
the XELOX regimen in terms of PFS in comparison with 
the FOLFOX4 regimen in metastatic CRC. When bevaci-
zumab became available for clinical use, the trial design 
was amended, and patients were also randomized to receive 
either bevacizumab (5 mg/kg biweekly with FOLFOX4, or 
7.5 mg/kg triweekly with XELOX) or placebo in addition to 
the assigned regimens (with unchanged dosages) (Figure 2). 
This amended design allowed to demonstrate the superiority 
of the treatments containing bevacizumab in comparison with 
those including placebo. Patients treated with XELOX, with 
or without bevacizumab, had a median PFS of 8.0 months in 
comparison with a median of 8.5 months for patients treated 
with FOLFOX4 with or without bevacizumab, and the haz-
ard ratio for progression was 1.04 (97.5% CI, 0.93–1.16), 
demonstrating the non-inferiority of the XELOX treatment. 
RR (independently conﬁ  rmed) was 39% for FOLFOX4, and 
37% for XELOX. XELOX produced a signiﬁ  cantly lower 
occurrence of severe neutropenia (7% vs 44%), but more 
severe diarrhea (20% vs 11%) than the FOLFOX4 regimen 
(Cassidy et al 2007). On the other hand, bevacizumab added 
to FOLFOX4 or XELOX did not increase the RR, which 
indeed was the same (38%) with bevacizumab or placebo. 
However, bevacizumab signiﬁ  cantly prolonged the overall 
PFS (from 8.0 to 9.4 months) in comparison with placebo 
(hazard ratio = 0.83, p = 0.0023). Excluding the occurrence 
of severe hypertension (3.7% vs 1.2%), toxicity was not 
signiﬁ  cantly worsened by the addition of bevacizumab (Salts 
et al 2007).
Other investigators assessed the combination of 
capecitabine with irinotecan in metastatic patients. Bajetta 
et al explored in a randomized phase II trial two schedules 
of administration for this combination: a total of 140 patients 
received capecitabine 2500 mg/m2 daily on days 2 to 15, and 
irinotecan at a dose of either 300 mg/m2 on day 1 (arm A) or 
150 mg/m2 on days 1 and 8 (arm B), recycling every 3 weeks. 
However, during the course of the study, capecitabine dosage 
was reduced to 2000 mg/m2/day in both arms, and irinotecan 
was reduced to 240 mg/m2 (arm A), or to 120 mg/m2 (arm B) 
in order to decrease the occurrence of severe diarrhea. RR 
was 47% in arm A, and 44% in arm B, while median PFS was 
similar in either arm (8.3 and 7.6 months) (Bajetta et al 2005). 
Similarly, the Swiss Group for Clinical Cancer Research 
randomly assessed two different schedules of irinotecan, 
either 70 mg/m2 weekly for 5 consecutive weeks (arm A), or 
300 mg/m2 (reduced to 240 mg/m2 in the course of the trial) 
every 3 weeks (arm B), in combination with capecitabine 
1000 mg/m2 twice daily, days 1–14 and days 22–35, every Therapeutics and Clinical Risk Management 2007:3(3) 426
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6 weeks. RR was comparable with the two regimens (34% 
and 25%, respectively). However, median PFS (6.9 vs 9.2 
months) and OS (17.4 vs 24.7months) were both in favor of 
arm B, which also caused less grade 3/4 diarrhea (arm A: 
34%, arm B: 19%) (Borner et al 2005).
More recently, the combination of capecitabine and 
irinotecan has been assessed in some randomized phase III 
trials. In one such trial, 430 patients were randomly assigned 
to receive one of 3 regimens: FOLFIRI (biweekly irinote-
can 180 mg/m2, LV 400 mg/m2, 5FU 400 mg/m2 i.v. bolus 
plus 2400 mg/m2 46-hour i.v. infusion); mIFL (irinotecan 
125 mg/m2, LV 20 mg/m2 and 5FU 500 mg/m2 for 2 weeks 
every 3); or CapIRI (irinotecan 250 mg/m2 on day 1 and 
capecitabine 2000 mg/m2 for 14 days, every 3 weeks). In all 
arms, patients were also randomized to receive or not cele-
coxib (a COX-2 inhibitor) given orally at 400 mg bid. The 
addition of celecoxib had no effect on activity and toxicity of 
each regimen. However, it is relevant to note that the CapIRI 
regimen produced an unacceptably higher occurrence of 
severe diarrhea and dehydration (48% and 19%) than either 
FOLFIRI (13% and 6%) or mIFL (19% and 7%) regimens. 
This observation led to the closure of this arm of the trial 
when bevacizumab was subsequently added (5 mg/kg 
biweekly, or 7.5 mg/kg triweekly) to the regimens on study. 
Therefore, in the second part of this trial, 117 patients were 
randomly allocated to receive either FOLFIRI + bevacizumab 
or mIFL + bevacizumab. Both regimens showed an increased 
activity in comparison with that previously reported without 
bevacizumab (RR was 57% and 69%, and PFS 9.9 and 8.3 
months, respectively) (Table 2) (Fuchs et al 2006).
The results of a similar trial of the EORTC were 
presented at the 2005 ASCO annual meeting: 85 patients 
were randomized to receive FOLFIRI or CapIRI ± celecoxib. 
The trial was early closed after this initial accrual due to the 
occurrence of 8 deaths not due to progressive disease. Six 
deaths (5 treatment-related ) occurred in the CapIRI arm, 
and 2 deaths (both treatment-related) in the FOLFIRI arm. 
In addition, 61% of patients starting the CapIRI treatment 
required dose reduction as opposed to only 7% of the 
FOLFIRI arm (Köhne et al 2005).
Capecitabine in the primary 
management of rectal cancer
The management of locally advanced rectal cancer has 
consistently changed in the last few years. Indeed, there is 
now a general agreement that a complete resection of the 
mesorectum (total mesorectal excision, TME) could reduce 
the risk of local relapse for patients operated with curative 
Trial NO16966
Recruitment
June 2003-May 2004
XELOX
N=317
FOLFOX4
N=317
N=350
FOLFOX4 + placebo FOLFOX4 + bevacizumab
N=349
XELOX + bevacizumab
N=350
Recruitment
February 2004-February 2005
XELOX + placebo
N=351
Protocol amended to 2x2 placebo controlled design
after bevacizumab phase III data became available
Initial 2-arm
open-label study
Figure 2 Flow chart of trial XELOX-1/NO16966.Therapeutics and Clinical Risk Management 2007:3(3) 427
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intent. However, even when an R0 resection with a TME is 
performed, a pre-operative short-term radiotherapy (RT) of 
the pelvis (5 Gy/day for 5 days) has been demonstrated to 
further reduce the 2-year risk of local failure after surgery in 
comparison with TME alone (2.4% vs 8.2%) (Kapiteijn et al 
2001). The beneﬁ  t of preoperative RT on OS is still debated, 
but recent meta-analyses on this issue have shown a modest 
but signiﬁ  cant reduction of the overall and cancer-speciﬁ  c 
mortality for patients receiving RT compared with those 
treated with surgery alone (Cammà et al 2000; Colorectal 
Cancer Collaborative Group 2001).
Following this observation, a German trial has demon-
strated that 2 cycles of 5FU 1000 mg/m2 delivered as con-
tinuous i.v. infusion for 5 days during the 1st and 5th week of 
preoperative RT (for a total dose of 50.4 Gy) was able to further 
reduce the local relapse (6% vs 13%) in comparison with the 
same postoperative chemo-irradiation treatment, although it 
produced no survival beneﬁ  t (Sauer et al 2004). Therefore, in 
many centers, preoperative chemo-radiotherapy is considered 
the standard treatment for poor-risk rectal cancer, on the basis 
of a reduced acute and chronic toxicity caused by the preopera-
tive as opposed to the postoperative approach. 
Based on this assumption, some investigators have assessed 
the replacement of 5FU with capecitabine during preoperative 
RT for rectal cancer. Das et al (2006) have retrospectively 
compared the safety and efﬁ  cacy of capecitabine delivered 
during RT in 89 patients with rectal cancer with those reported 
in a matched series of 89 patients previously treated with 
infusional 5FU, reporting a similar low occurrence of grade 
3–4 toxicity, and comparable local and distant failure rates. 
De Paoli et al (2006) prospectively evaluated such combined 
treatment, with capecitabine given 825 mg/m2 twice daily 
during pelvic RT (50.4 Gy in 28 fractions) for high risk rectal 
cancer. A downstaging was reported in 57% of patients, and 
a pCR in 24%. Treatment was feasible, with only 6 patients 
(11%) suffering from grade 3 toxicity. The same combina-
tion of capecitabine 825 mg/m2 twice daily and pelvic RT 
(52.5 Gy) was assessed in 54 patients (51 underwent surgery): 
9 patients (24%) achieved a pCR, and 12 patients (24%) a 
pTmic. Diarrhea occurred in 2% of patients (Khrishnan et al 
2006). Finally, Kim et al (2006) reported on the comparative 
activity of 5FU/LV or capecitabine during preoperative RT for 
rectal cancer (50.4 Gy) in 278 patients. A complete (11.3% vs 
16.1%) or nearly complete (12.9% vs 12.9%) tumor regression 
occurred in similar proportions of patients (Table 5). 
Other investigators are now assessing the combination 
of other active drugs such as oxaliplatin or irinotecan with 
infusional 5FU or oral capecitabine to primary rectal RT.
Gérard et al (2003) have reported on the administra-
tion of oxaliplatin 130 mg/m2 plus a 5-day i.v. infusion 
of 5FU 350 mg/m2 daily and L-LV 100 mg/m2 daily for 2 
cycles on the 1st and 5th week of pelvic RT (50 Gy) in 40 
patients. This regimen was well tolerated, and no residual 
tumor was seen in 15% of patients). Aschele et al (2005) 
in a phase I-II study found that the recommended dose for 
weekly oxaliplatin in addition to 5FU (225 mg/m2 daily in 
continuous infusion during pelvic RT) was 60 mg/m2. They 
treated 25 patients with this regimen, and reported a 28% 
pathologic complete response (pCR) with only mild (grade 3) 
diarrhea in 16% of them. A similar phase I-II study was also 
conducted by Ryan et al (2006) on behalf of the Cancer and 
Leukemia Group B: also in this case, the recommended dose 
Table 3 Comparative severe toxicity reported in the TREE-1 and TREE-2 trials (Hochster et al 2006)
Patients (%)  TREE-1 trial  TREE-2 trial 
  mFOLFOX  bFOL  XELOX  mFOLFOX +   bFOL +   XELOX+ 
  (n = 49)  (n = 50)  (n = 48)  bevacizumab  bevacizumab  bevacizumab
        (n = 71)  (n = 70)  (n = 72) 
Neutropenia 53  18  15  49  19  10
Dehydration 8  12  27  6  14  8
Diarrhoea 33  26  31  13  26  19
Hypertension 0  0  2  7  13  15
TE, arterial   2  0  0  0  0  3
TE, other  10  4  2  10  10  4
Nausea 16  14  19  6  11  11
Vomiting 14  10  19  1  13  10
Neurotoxicity 18  10  23  14  11  15
Hand–foot syndrome  8  2  19  0  0  10
Any grade 3/4  96  76  85  85  74  76
Abbreviations: TE, thromboembolic events.Therapeutics and Clinical Risk Management 2007:3(3) 428
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for oxaliplatin was 60 mg/m2 weekly in combination with 
5FU 200 mg/m2/day as continuous i.v. infusion during pelvic 
preoperative RT (50.4 Gy). Among 32 patients treated with 
these dosages in the phase II study, a pCR was reported in 
25% of them; however, 12 patients (38%) experienced grade 
3 or 4 diarrhea.
The combination of oxaliplatin and capecitabine, delivered 
during preoperative pelvic RT for poor-risk rectal cancer, 
has been explored by several investigators in phase I-II trials. 
All these studies reported encouraging pCR rates, but con-
ﬂ  icting results about tolerability. Indeed, Rödel et al (2003) 
conducted a phase I/II study to deﬁ  ne the optimal oxaliplatin 
dose to deliver on days 1 and 8 of a 2-week administration 
of capecitabine (825 mg/m2 twice daily) for 2 cycles during 
pelvic RT (50.4 Gy). The recommended dosage for oxaliplatin 
was 50 mg/m2, and 26 patients were treated with this regimen: 
severe diarrhea occurred in only 8% of them. 
Machiels et al (2005) have treated 40 patients with oxali-
platin 50 mg/m2 weekly for 5 weeks plus capecitabine 825 
mg/m2 twice daily during pelvic RT (total dose, 45 Gy); pCR 
was seen in 14% of patients with such treatment; however, 
severe diarrhea occurred in 30% of treated patients. 
Glynne-Jones et al (2005) reported on a phase II trial 
assessing the addition of two doses of oxaliplatin 130 mg/
m2, 4 weeks apart, during pelvic RT (45 Gy in 5 weeks) as-
sociated with a continuous assumption of capecitabine (650 
mg/m2 twice daily), followed by surgery. Ninety-ﬁ  ve patients 
were treated, and 85 underwent surgery: a pCR was achieved 
in 16 (19%) patients, and a Tmic was found at the pathologic 
examination in additional 21 (25%) patients. 
Rutten et al (2006) presented the results of the CORE 
(capecitabine, oxaliplatin, radiotherapy, and excision) study. 
Eighty-ﬁ  ve patients with poor-risk rectal cancer were treated 
with weekly oxaliplatin 50 mg/m2 and twice daily capecitabine 
825 mg/m2, followed by TME, and 6 postoperative cycles of 
XELOX.  These investigators reported a pCR in 11.5% of 
patients, and stressed the good tolerability of such treatment, 
with grade 3–4 diarrhea reported in 16% of patients. 
A phase II trial published by Chau et al reported the safety 
and activity of 4 cycles of XELOX (oxaliplatin 130 mg/m2 
plus capecitabine 2000 mg/m2 daily for 2 weeks), followed 
by capecitabine 1650 mg/m2 daily during pre-operative RT in 
77 patients affected by rectal cancer, most of whom with poor 
risk factor for recurrence. Among 67 patients who underwent 
surgical resection, pT0 was reported in 18 patients (27%), 
and pathologically negative lymph nodes were found in 29 
patients with initial clinical nodal involvement (Chau et al 
2006). The NSABP R-04 trial is currently comparing, in a 
2 × 2 factorial design, the combination of 5FU in continuous 
i.v. infusion vs capecitabine, with or without oxaliplatin, and 
preoperative RT for poor risk rectal cancer.
On the other hand, the addition of irinotecan to 5FU dur-
ing preoperative pelvic RT for locally advanced rectal cancer 
has been assessed by the Radiation Therapy Oncology Group 
(RTOG) trial 0012. In this study, 106 patients randomly 
received either hyperfractionated bid pelvic RT (total dose, 
45.6 Gy plus boost of 9.6 Gy) with 5FU (225 mg/m2 daily) 
continuous i.v. infusion, or a single daily fraction of pelvic 
RT (total dose, 45 Gy plus boost of 5.4 Gy) with 5FU (225 
mg/m2 daily i.v. infusion for 5 days a week) and irinotecan 
(50 mg/m2 weekly × 4 weeks). The same proportion of pCR 
(26%) was reported in either arm, and no substantial differ-
ence in occurrence and/or severity of toxicity was reported 
(Mohiuddin et al 2006). This observation prompted other 
investigators to assess the combination of weekly irinotecan 
50 mg/m2 with capecitabine during three-dimensional con-
formal pelvic RT (50.4 Gy). Indeed, Hofheinz et al (2005) 
performed a dose-ﬁ  nding trial for this combination added to 
Table 4 Comparative activity and toxicity of the assessed regimens before and after the addition of bevacizumab (Fuchs et al 2006) 
Results  Without bevacizumab ± celecoxib   With bevacizumab ± celecoxib
  FOLFIRI  mIFL  CapIRI  FOLFIRI +  mIFL +
  n = 144  n = 141  n = 145  bevacizumab  bevacizumab 
        n = 57  n = 60
Response rate  47%  42%  38%  54%  53%
PFS months  7.6  5.8  5.5  9.9  8.3
OS months  23.1  17.6  18.9  NR  18.7
Diarrhoea 13%  19%  48%  11%  12%
Dehydration 6%  7%  19%  5%  2%
Neutropenia 40%  39%  31%  52%  29%
60-day mortality   2.9%  5.8%  3.5%  1.8%  6.8%
Abbreviations: OS, overall survival; PFS, progression-free survival.Therapeutics and Clinical Risk Management 2007:3(3) 429
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pelvic RT. They identiﬁ  ed as the dose limiting toxicity the 
occurrence of severe diarrhea, and recommended a dosage 
of capecitabine of 500 mg/m2 bid for subsequent evaluation. 
Thirty-six patients were thereafter treated with this regimen, 
and 28 patients underwent surgery: a pCR was reported in 
5/28 (18%) patients (Willeke et al 2007). Diarrhea was the 
dose limiting toxicity also in the phase I/II trial of Klautke 
et al (2006), in which the recommended dose was 750 
mg/m2 twice daily for capecitabine, and 40 mg/m2 weekly 
for irinotecan. In this study, a pCR was reported in 15% of 
patients. Gollins et al (2006) also conducted a phase I/II trial, 
recommending 60 mg/m2 i.v. weekly for 4 weeks for irinote-
can, and 650 mg/m2 twice daily for oral capecitabine; these 
investigators reported that 9 of 40 (22.5%) patients eligible 
for resection showed a pCR with this combination. 
Capecitabine in the adjuvant 
management of colon cancer
For several years, a 6-month treatment with the Mayo Clinic 
regimen has been considered the standard adjuvant man-
agement for patients who underwent curative surgery for 
high-risk stage II and for stage III colon cancer, because is 
has been proven to reduce the risk of recurrence and death. 
This treatment appeared as effective in young as in elderly 
patients, although older patients are less likely to receive an 
adjuvant treatment, because of concern regarding tolerability 
on this group. 
Based on the superior RR and improved safety in meta-
static patients, capecitabine has also been evaluated in the 
adjuvant setting. The Capecitabine Adjuvant Chemotherapy 
for Colon Cancer Trial (X-ACT) evaluated capecitabine 
1250 mg/m2 twice daily, from day 1 to 14, every 21 days 
vs the Mayo Clinic regimen: LV 20 mg/m2 followed by 
5FU 425 mg/m2, administered as an i.v. bolus on days 1–5 
every 28 days in resected stage III colon cancer. Total treat-
ment duration was 24 weeks. The primary end-point of the 
trial was to show that disease-free survival is at least as 
equivalent with capecitabine as with 5FU/LV. This result 
was clearly met, because the hazard ratio was 0.87 (95% 
CI, 0.75–1.00). Compared with the targeted upper limit of 
the CI of 1.20, capecitabine resulted equivalent to 5FU/LV 
(p < 0.001). Moreover, capecitabine showed a strong trend 
to superior disease-free survival (p = 0.0528). At 3 years, 
3.6% more patients receiving capecitabine were disease-free 
compared with the 5-5FU/LV group. Adjuvant capecitabine 
offered signiﬁ  cantly superior relapse-free survival (hazard 
ratio = 0.86, p = 0.0407) vs 5FU/LV. There was also a trend 
toward superior overall survival with capecitabine (hazard 
ratio = 0.84, p = 0.0706). The safety of adjuvant capecitabine 
was greater, with a low rate of treatment-related mortality 
(0.3%). The only clinical adverse event more commonly 
seen with capecitabine was the hand-foot syndrome, which, 
however, was never life threatening (Twelves et al 2005b).
The XELOX regimen has been compared with standard 
5FU/LV regimens (Mayo Clinic or Roswell Park) as adjuvant 
treatment in stage III colon cancer. Safety analysis of this 
study has recently been published: occurrence of grade 3 
toxicity was in favor of the XELOX regimen for neutropenia 
(5.3% vs 10.9%), febrile neutropenia (0.2% vs 3.8%), and 
severe stomatitis (0.6% vs 7.9%); however, the XELOX pro-
duced more skin (3.6% vs 0.2%) and neurosensory toxicity 
(8.1% vs 0%) (Schmoll et al 2007).
Given the ﬁ  ndings of the MOSAIC trial, showing a 
3-year reduced risk of recurrence with a 6-month adjuvant 
FOLFOX4 treatment in operated stage II and III colon cancer 
patients (André et al 2004), this regimen now represents the 
new backbone on which to build up new adjuvant strategies. 
Indeed, on the basis of the above-mentioned safety results 
of XELOX in the adjuvant setting (Schmoll et al 2007), 
the AVANT trial is currently evaluating the addition of 
bevacizumab (biweekly or triweekly) to either FOLFOX4 or 
XELOX adjuvant treatment in stage II-III colon cancer.
Oral therapy is preferred by 
patients and is cost-effective
The preference of patients for an oral therapy, provided that it is 
equally effective as i.v. therapy, has already been reported (Liu 
et al 1997; Borner et al 2002; Twelves et al 2006). Moreover, 
several pharmacoeconomic analyses conducted in different 
countries and from different healthcare perspectives have 
shown that capecitabine is associated with reduced costs com-
pared with 5FU/LV in both the adjuvant and palliative setting 
(Twelves et al 2001; Cassidy et al 2006; Egginton et al 2006; 
Ward et al 2006). Most cost savings were attributable to the 
reduced administration costs. These data support the inclusion 
of capecitabine in the clinical armamentarium for the treatment 
of metastatic as well as adjuvant CRC. The additional cost of the 
combination oxaliplatin with capecitabine could be counterbal-
anced by the lower incidence of some treatment-related adverse 
events with this regimen in comparison with the FOLFOX4 
regimen. Future research should attempt to elucidate the optimal 
role of bevacizumab in addition to XELOX or FOLFOX in the 
adjuvant as well in the palliative setting in order to achieve the 
maximum level of clinical beneﬁ  t.Therapeutics and Clinical Risk Management 2007:3(3) 430
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